Regulatory

CLINUVEL
Posted by CLINUVEL
October 8, 2021

CLINUVEL PHARMACEUTICALS LTD 2021 Annual General Meeting - Notice of Meeting & Explanatory Memorandum

Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
September 16, 2021

Notification regarding unquoted securities - CUV

Melbourne, Australia, 16 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2021

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021

Melbourne, Australia, 27 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Corporate Presentation - FY2021 Results

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Appendix 4E and Preliminary Financial Report

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Delivers Record Revenues and Profit

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Dividend/Distribution - CUV

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – CLINUVEL to Trial Innovative Drug in Stroke

The drug afamelanotide will be used for the first time in patients...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – TGA approves Australian drug to protect patients from light and sun

New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Australian TGA approves SCENESSE®

Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release – New drug to repair damaged skin and reduce skin cancer risk

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...

Read More